ReviewImmunological reviews2011
Immunization delivered by lentiviral vectors for cancer and infectious diseases.
Review in Immunological reviews, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
52 citing papers in PubMed.
- Extended follow-up of in vivo BCMA CAR-T therapy in relapsed/refractory multiple myeloma.Nature medicine · 2026Article
- Advances in oncolytic viruses immunotherapy of hepatocellular carcinoma.Discover oncology · 2026Review
- Beyond reverse transcription: molecular mechanisms and emerging paradigms in retroviral replication.FEMS microbiology reviews · 2026Review
- Dendritic-cell-targeting virus-like particles as potent mRNA vaccine carriers.Nature biomedical engineering · 2025Article
- Viral Vector-Based Cancer Vaccines.Methods in molecular biology (Clifton, N.J.) · 2025Article
- Viral vector- and virus-like particle-based vaccines against infectious diseases: A minireview.Heliyon · 2024Review
- Vaccine delivery systems and administration routes: Advanced biotechnological techniques to improve the immunization efficacy.Vaccine: X · 2024Review
- Progression of oncolytic virus in liver cancer treatment.Frontiers in oncology · 2024Review
- Article
- Lentiviral Vectors as a Vaccine Platform against Infectious Diseases.Pharmaceutics · 2023Review
- An intranasal lentiviral booster reinforces the waning mRNA vaccine-induced SARS-CoV-2 immunity that it targets to lung mucosa.Molecular therapy : the journal of the American Society of Gene Therapy · 2022Article
- A lentiviral vector expressing a dendritic cell-targeting multimer induces mucosal anti-mycobacterial CD4Mucosal immunology · 2022Article
- Safety and efficiency modifications of SIV-based integrase-defective lentiviral vectors for immunization.Molecular therapy. Methods & clinical development · 2021Article
- Brain cross-protection against SARS-CoV-2 variants by a lentiviral vaccine in new transgenic mice.EMBO molecular medicine · 2021Article
- Nanovaccine Delivery Approaches and Advanced Delivery Systems for the Prevention of Viral Infections: From Development to Clinical Application.Pharmaceutics · 2021Review
- Intranasal vaccination with a lentiviral vector protects against SARS-CoV-2 in preclinical animal models.Cell host & microbe · 2021Article
- Article
- Preclinical Progress of Subunit and Live AttenuatedPharmaceutics · 2020Review
- Production of Lentiviral Vectors Using Suspension Cells Grown in Serum-free Media.Molecular therapy. Methods & clinical development · 2020Article
- Role of Purine-Rich Regions in Mason-Pfizer Monkey Virus (MPMV) Genomic RNA Packaging and Propagation.Frontiers in microbiology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The increasing level of understanding of the lentivirus biology has been instrumental in shaping the design strategy of creating therapeutic lentiviral delivery vectors. As a result, lentiviral vectors have become one of the most powerful gene transfer vehicles. They are widely used for therapeutic purposes as well as in studies of basic biology, due to their unique characteristics. Lentiviral vectors have been successfully employed to mediate durable and efficient antigen expression and presentation in dendritic cells both in vitro and in vivo, leading to the activation of cellular immunity and humoral responses. This capability makes the lentiviral vector an ideal choice for immunizations that target a wide range of cancers and infectious diseases. Further advances into optimizing the vector system and understanding the relationship between the immune system and diseases pathogenesis will only augment the potential benefits and utility of lentiviral vaccines for human health.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.